GlassScriptPhysician profile
Debra D Kosko
NPI 1275588097
$888.72
in general payments reported to CMS, 2019-2025
15 companies · $560 in 2025
The $560 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $219 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $262.81 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $251.16 | 2023-2025 | Carvykti, Erleada, Rybrevant |
| Pfizer INC. | $59.46 | 2025 | |
| Daiichi Sankyo INC. | $52.93 | 2024-2025 | Injectafer, Enhertu |
| Beone Medicines USA, INC. | $39.76 | 2025 | Tevimbra |
| Tempus Ai, INC | $30.23 | 2025 | Xt Cdx |
| Genzyme Corporation | $29.11 | 2025 | |
| Lilly USA, LLC | $28.11 | 2023 | Retevmo, Jaypirca, Verzenio |
| Beigene USA, INC. | $24.80 | 2025 | Brukinsa |
| Celgene Corporation | $20.66 | 2023 | Reblozyl |
| Caris Mpi, INC. | $19.14 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $19.03 | 2024 | |
| Astellas Pharma US INC | $17.76 | 2025 | Padcev |
| Abbvie INC. | $17.38 | 2025 | |
| Gilead Sciences, INC. | $16.38 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Kosko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.